Whey

For diagnostic purposes, the dosage of Whey allergenic extract is not measured in milligrams but in volume and concentration.

• Skin Prick Testing (SPT): One drop (approximately 0.05 mL) of the 1:10 or 1:20 w/v extract is applied to the skin, typically on the forearm or back. A sterile lancet is then used to prick the skin through the drop.
• Intradermal Testing: If the SPT is negative but clinical suspicion remains high, a healthcare provider may administer 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) intradermally, creating a small bleb (bubble) on the skin.

Whey allergenic extract is frequently used in children, as milk allergy is a primary concern in pediatric nutrition. The procedure is identical to the adult dosage, though the back is often preferred over the forearm in infants to provide a larger surface area and prevent the child from touching the test sites. Healthcare providers may adjust the number of tests performed simultaneously in very young children to minimize discomfort.

Renal Impairment

No dosage adjustments are required for patients with renal impairment, as the systemic absorption of the diagnostic extract is minimal. However, the patient's overall health should be stable before testing.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment. The localized nature of the test does not rely on hepatic metabolism.

Elderly Patients

In elderly patients, skin reactivity may be diminished due to age-related changes in skin turgor and mast cell density. While no specific dose adjustment is required, the healthcare provider must interpret the results cautiously, often relying more heavily on the positive control (histamine) to validate the test's accuracy.

Whey allergenic extract is never self-administered. It must be administered by a trained healthcare professional, such as an allergist or a specialized nurse.

• Preparation: The skin site (usually the forearm or back) is cleaned with an alcohol swab and allowed to dry.
• Application: The extract is applied using a dropper or a multi-test device.
• Observation: The patient must remain in the clinic for at least 30 minutes following the application. The results are typically read between 15 and 20 minutes after the prick is made.
• Storage: The extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It should not be frozen. Exposure to room temperature should be minimized to prevent loss of potency.

Since Whey is used as a one-time diagnostic test, 'missed doses' in the traditional sense do not occur. If a diagnostic appointment is missed, it should be rescheduled. If a skin test fails to produce a reaction in the positive control (histamine), the test is considered invalid and must be repeated at a later date once interfering factors (like antihistamine use) are removed.

An 'overdose' of Whey allergenic extract in a diagnostic setting would involve either the use of an excessively high concentration for intradermal testing or the application of the extract to an excessively large area of skin.

• Signs of Overdose: Excessive localized swelling, rapid onset of hives (urticaria) beyond the test site, or systemic symptoms such as wheezing, throat tightness, or hypotension (low blood pressure).
• Emergency Measures: If systemic symptoms occur, the extract should be wiped off the skin immediately. The healthcare provider will administer epinephrine (adrenaline) intramuscularly and may provide supplemental oxygen, intravenous fluids, and antihistamines. Emergency medical services (911) should be contacted if the reaction occurs outside a hospital setting.

> Important: Follow your healthcare provider's dosing instructions. Do not attempt to use allergenic extracts outside of a supervised medical environment.

Because Whey allergenic extract is designed to elicit a localized immune response, certain 'side effects' are actually the intended diagnostic outcome.

• Localized Wheal: A raised, pale, or skin-colored bump at the site of the test. This usually feels like a mosquito bite and is itchy. It typically appears within 15 minutes and resolves within 1 to 2 hours.
• Localized Flare: Redness (erythema) surrounding the wheal. This is caused by increased blood flow to the area and can feel warm to the touch.
• Pruritus (Itching): Intense itching at the test site is very common and is a direct result of histamine release.

• Persistent Redness: In some patients, the redness at the test site may last for 24 to 48 hours. This is often referred to as a 'late-phase reaction.'
• Small Blisters: Occasionally, a very strong positive reaction can lead to the formation of small fluid-filled blisters (vesicles) at the prick site.
• Localized Swelling: Swelling that extends slightly beyond the immediate flare area, especially in patients with high sensitivity.

• Lymphangitis: Very rarely, red streaks may extend from the test site toward the nearest lymph node, indicating a significant inflammatory response.
• Vasovagal Reaction: Fainting or lightheadedness due to the stress of the skin prick or the sight of the needle/lancet, rather than a reaction to the whey itself.

While rare during skin prick testing, systemic reactions can occur and are life-threatening.

> Warning: Stop the procedure and seek emergency care if you experience any of the following:

• Anaphylaxis: A severe, whole-body allergic reaction. Symptoms include a rapid pulse, a sudden drop in blood pressure, and difficulty breathing.
• Angioedema: Deep swelling, particularly of the lips, tongue, or throat, which can obstruct the airway.
• Generalized Urticaria: Hives appearing on parts of the body far away from the test site.
• Bronchospasm: Sudden constriction of the airways, causing wheezing, chest tightness, and shortness of breath.
• Hypotension: Feeling extremely dizzy, weak, or fainting due to a drop in blood pressure.

There are no known long-term side effects associated with the one-time diagnostic use of Whey allergenic extract. It does not cause permanent changes to the immune system or increase the baseline severity of a milk allergy. Repeated testing over years is generally considered safe.

While Whey allergenic extract itself may not always carry a specific black box warning on every brand's label, the class of Allergenic Extracts often carries a general warning regarding the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients should be observed for at least 30 minutes after administration. These products should only be administered by healthcare professionals prepared to treat anaphylaxis. Patients with unstable asthma are at higher risk for severe reactions.

Report any unusual symptoms or delayed reactions (occurring hours after the test) to your healthcare provider immediately.

Whey allergenic extract is a diagnostic tool, not a treatment. It must be used with extreme caution in patients who have a history of severe, life-threatening reactions to milk. The most critical safety consideration is the potential for the diagnostic test itself to trigger a systemic allergic reaction. Patients should be in their baseline state of health before undergoing testing; for example, an active asthma flare or a recent viral infection can increase the risk of a severe reaction to the skin test.

No FDA black box warnings specifically for 'Whey' as a standalone ingredient exist, but the Non-Standardized Food Allergenic Extract class is subject to the general warnings for all allergenic extracts. These warnings emphasize that the product is intended for use by physicians who are experienced in the administration of allergenic extracts and the treatment of anaphylaxis.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is a systemic IgE-mediated reaction. This is more common with intradermal testing than with skin prick testing. Healthcare providers must have 'crash carts' containing epinephrine, antihistamines, and airway management equipment ready.
• Asthma Status: Patients with poorly controlled or unstable asthma are at a significantly higher risk for a fatal systemic reaction if they experience anaphylaxis during the skin test. Testing should be postponed until asthma is well-controlled.
• Skin Conditions: Testing should not be performed on skin areas affected by active dermatitis, eczema, or psoriasis, as these conditions can cause false-positive results or interfere with the interpretation of the wheal and flare.
• Dermatographism: Some patients have 'skin writing' (dermatographism), where any physical pressure on the skin causes a hive. In these patients, the skin test may yield false positives.

• Immediate Observation: The patient must be monitored visually for at least 30 minutes following the test.
• Vital Signs: In high-risk patients, blood pressure and heart rate may be monitored before and after the procedure.
• Lung Function: For patients with asthma, a peak flow meter or spirometry may be used to ensure lung function is stable prior to testing.

Whey allergenic extract does not typically affect the ability to drive or operate machinery. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction requiring medication (like sedating antihistamines or epinephrine), they should not drive until fully recovered and cleared by a physician.

There is no direct chemical interaction between alcohol and Whey extract. However, alcohol consumption can cause vasodilation and may theoretically increase the rate of absorption of the allergen or exacerbate the redness of a flare. It is generally advised to avoid alcohol on the day of the test to ensure clear results.

As this is a diagnostic test, discontinuation refers to stopping the procedure. If a patient begins to show signs of a systemic reaction (e.g., coughing, sneezing, itching in areas other than the test site), the extract must be wiped off immediately, and no further testing should be conducted during that session.

> Important: Discuss all your medical conditions and current medications with your healthcare provider before starting Whey diagnostic testing.

There are no drugs that are strictly 'contraindicated' in the sense of causing a lethal chemical reaction with Whey. However, certain drugs make the test unsafe or uninterpretable:

• Beta-Blockers (e.g., Propranolol, Metoprolol): While not a direct interaction with the whey, beta-blockers can make a patient resistant to the effects of epinephrine. If the patient has a severe reaction to the whey extract, the life-saving treatment (epinephrine) may not work effectively. Many allergists will not perform skin testing on patients taking beta-blockers.

• Tricyclic Antidepressants (TCAs) (e.g., Amitriptyline, Nortriptyline): These medications have potent antihistamine properties that can last for weeks. They can completely suppress the skin's reaction to the whey extract, leading to a false-negative result. These should typically be discontinued 7 to 14 days before testing, under a doctor's supervision.
• ACE Inhibitors (e.g., Lisinopril): Similar to beta-blockers, ACE inhibitors may interfere with the body's compensatory mechanisms during anaphylaxis and may increase the severity of a systemic reaction.

• Antihistamines (H1 Blockers): Drugs like Loratadine (Claritin), Cetirizine (Zyrtec), and Fexofenadine (Allegra) will suppress the wheal and flare response. These must be stopped 3 to 7 days before testing.
• H2 Blockers: Medications like Famotidine (Pepcid) can also slightly decrease the skin's response and are usually stopped 24 to 48 hours before testing.
• Topical Corticosteroids: Applying steroid creams to the test site will suppress the local immune response. These should be avoided on the test area for at least 2 to 3 weeks.

• Dairy Products: There is no interaction between eating dairy and the skin test itself; however, if a patient is undergoing a skin test, they are likely already avoiding dairy due to allergy concerns. Consuming dairy shortly before a test might confuse the clinical picture if the patient develops GI symptoms or hives from the food while the test is being performed.

• High-Dose Vitamin C: Some studies suggest very high doses of Vitamin C may have a mild antihistamine effect, potentially dampening the skin test result.
• St. John's Wort: May affect skin sensitivity in some individuals, though the clinical significance for allergenic testing is low.

Whey extract testing does not interfere with standard blood chemistry or hematology tests. However, it will interfere with other skin tests (like a TB skin test) if performed on the same site. It is also important to note that a positive skin test only indicates 'sensitization' (the presence of IgE) and must be correlated with clinical history to diagnose a 'food allergy.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for allergies, depression, or blood pressure.

Whey allergenic extract must NEVER be used for skin testing in the following circumstances:

• History of Severe Anaphylaxis to Skin Testing: If a patient has previously had a life-threatening systemic reaction to a skin prick test for milk or whey, further skin testing is generally considered too dangerous. In vitro (blood) testing (e.g., ImmunoCAP) is preferred.
• Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) of less than 70% of predicted, or those experiencing an acute asthma exacerbation, are at an unacceptable risk for fatal bronchospasm during testing.
• Acute Urticaria: Testing should not be done while a patient is currently covered in hives, as the background skin activity makes the test impossible to read and increases the risk of a systemic flare.

Conditions requiring careful risk-benefit analysis include:

• Pregnancy: While not strictly forbidden, skin testing is often postponed until after delivery to avoid the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby).
• Severe Atopic Dermatitis: If there is no clear area of healthy skin on the back or arms, the test results will be unreliable.
• Beta-Blocker Therapy: As noted in the interactions section, the inability to treat anaphylaxis effectively makes this a significant relative contraindication.

Patients who are sensitive to Whey allergenic extract are almost always cross-sensitive to:

• Whole Cow's Milk: Whey is a component of milk.
• Casein: The other major protein in milk; most milk-allergic patients react to both.
• Other Mammalian Milks: There is high cross-reactivity between whey proteins in cow's milk and those in goat's milk and sheep's milk. Testing for one often implies sensitivity to the others.

> Important: Your healthcare provider will evaluate your complete medical history and current health status before deciding to proceed with Whey diagnostic testing.

Whey allergenic extract is classified as Pregnancy Category C (using the older FDA system). There are no adequate and well-controlled studies in pregnant women. The primary concern is not the direct effect of the whey proteins on the fetus, but the potential for a systemic reaction (anaphylaxis) in the mother. Anaphylaxis can cause a sudden drop in maternal blood pressure, leading to placental hypoperfusion and fetal distress or death. Therefore, diagnostic skin testing for food allergies is typically deferred until the postpartum period unless the information is critical for the immediate management of the mother's health.

It is not known whether the proteins from a localized skin test are excreted in human milk. However, given the minute quantities used and the localized nature of the administration, it is highly unlikely to affect a nursing infant. The risk-benefit profile generally favors allowing testing if necessary, though many providers still choose to wait if the situation is not urgent.

Whey allergenic extract is widely used and FDA-approved for use in children, including infants. Milk allergy is the most common food allergy in the first year of life.

• Safety: Skin prick testing is considered safe in infants, though the risk of systemic reactions, while low, must always be prepared for.
• Interpretation: Infants may have smaller wheals than adults. A wheal diameter of 3mm or greater is generally considered positive, but in very young infants, even smaller reactions may be clinically significant.
• Growth Effects: There are no known effects on growth or development from diagnostic testing.

In patients over age 65, the skin's immunological reactivity tends to decrease. This can result in smaller wheal and flare reactions, potentially leading to false negatives.

• Polypharmacy: Elderly patients are more likely to be on beta-blockers or ACE inhibitors for cardiovascular disease, which increases the risk profile of the test.
• Skin Integrity: Fragile skin in the elderly may bleed more easily during the prick test, which can obscure the results.

Renal impairment does not affect the localized IgE-mediated response. No dose adjustments are needed. However, patients with end-stage renal disease (ESRD) may sometimes have 'uremic pruritus' (itching due to kidney failure), which can make the interpretation of an itchy skin test difficult.

There are no specific considerations for hepatic impairment. The diagnostic proteins are not processed by the liver in a way that would require dose modification or change the safety profile of the skin test.

> Important: Special populations require individualized medical assessment by an allergy specialist to ensure the highest level of safety.

Whey allergenic extract functions as a diagnostic antigen. Its molecular mechanism involves the binding of whey proteins—primarily Beta-lactoglobulin (Bos d 5) and Alpha-lactalbumin (Bos d 4)—to the Fab (fragment antigen-binding) portion of IgE antibodies. These IgE antibodies are 'sensitized' and bound to the high-affinity FcεRI receptors on the surface of cutaneous mast cells.

When at least two IgE antibodies are cross-linked by a single whey protein molecule, it triggers a transmembrane signal that activates phospholipase C. This leads to an influx of calcium ions into the mast cell, causing the fusion of intracellular granules with the cell membrane. This process, known as degranulation, releases histamine, proteases, and chemotactic factors into the surrounding tissue. The histamine binds to H1 receptors on local blood vessels, causing the characteristic 'wheal' (edema) and 'flare' (vasodilation).

• Dose-Response: There is a general correlation between the concentration of the extract and the size of the wheal, but this is highly individual. A person with high levels of specific IgE will react strongly even to very dilute extracts.
• Time to Onset: The reaction begins within seconds of the prick, with the wheal reaching its maximum size at 15–20 minutes.
• Duration of Effect: The visible reaction typically fades within 1 to 2 hours as the mediators are metabolized and the fluid is reabsorbed.
• Tolerance: Repeated skin testing does not lead to tolerance; however, if tests are performed too frequently at the same site, local mast cell depletion could theoretically occur.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Local administration) |

| Protein Binding | N/A (Localized to tissue) |

| Half-life | 30–60 minutes (Localized mediators) |

| Tmax | 15–20 minutes (Peak wheal size) |

| Metabolism | Local Proteolysis |

| Excretion | Lymphatic clearance |

• Molecular Components: A mixture of proteins with molecular weights ranging from 14 kDa (Alpha-lactalbumin) to 18 kDa (Beta-lactoglobulin) and up to 67 kDa (Bovine Serum Albumin).
• Solubility: Highly soluble in aqueous buffers and glycerin-saline solutions.
• Preparation: Prepared by aqueous extraction of bovine whey, followed by filtration and sterilization. It is non-standardized, meaning its potency is expressed as weight of source material per volume of extracting fluid (e.g., 1:20 w/v).

Whey belongs to the Non-Standardized Food Allergenic Extract [EPC] class. Related medications include other food extracts like Casein, Whole Milk, Egg White, and Peanut extracts. It is distinct from 'Standardized' extracts like those for Grass Pollen or Dust Mites, which have federally mandated potency units.